Abstract
Recent evidence confirms that not each tumor cell is proficient in instigating a tumor. Merely a small part of the cancer cells, so-called cancer stem cells (CSCs), can produce cancer indistinguishable from the first one. CSC model has been recognized as a cellular component that adds to phenotypic and functional heterogeneity in different cancers. The latest explanations have featured numerous complexities and difficulties like CSC phenotype that can differ extensively between patients. Tumors may harbor various phenotypically or genetically specific CSCs, and consequently, metastatic CSCs can develop from vital CSCs and tumor cells. Scientists have discovered a few markers for CSCs. The recent finding reveals that CSCs are resistant to radiotherapy and chemotherapy and may clarify the disease's reappearance. Minimal amounts of CSCs can repopulate a tumor. Subsequently, it is essential to understand the attributes and mechanisms by which CSCs show their resistance to therapeutic agents. These aptitudes contribute to new bits of knowledge that give better therapeutic motivations to discover novel anticancer therapeutics. Accordingly, remedial procedures that emphasize focusing on CSCs and their microenvironmental niche are insufficient for conventional malignant growth treatments to eradicate the CSCs that, in any case, bring about therapy resistance. Mutual utilization of traditional therapies with CSC- specific agents may offer a promising technique for enduring cancer treatment as well as remedy.
Keywords: Cancer stem cells, instigation, cancer markers, therapeutic agents, anticancer therapeutics, promising technique.
Current Stem Cell Research & Therapy
Title:Cancer Stem Cells: Current Status and Therapeutic Implications in Cancer Therapy-A New Paradigm
Volume: 16 Issue: 8
Author(s): Suman Kumar Ray and Sukhes Mukherjee*
Affiliation:
- Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh- 462020,India
Keywords: Cancer stem cells, instigation, cancer markers, therapeutic agents, anticancer therapeutics, promising technique.
Abstract: Recent evidence confirms that not each tumor cell is proficient in instigating a tumor. Merely a small part of the cancer cells, so-called cancer stem cells (CSCs), can produce cancer indistinguishable from the first one. CSC model has been recognized as a cellular component that adds to phenotypic and functional heterogeneity in different cancers. The latest explanations have featured numerous complexities and difficulties like CSC phenotype that can differ extensively between patients. Tumors may harbor various phenotypically or genetically specific CSCs, and consequently, metastatic CSCs can develop from vital CSCs and tumor cells. Scientists have discovered a few markers for CSCs. The recent finding reveals that CSCs are resistant to radiotherapy and chemotherapy and may clarify the disease's reappearance. Minimal amounts of CSCs can repopulate a tumor. Subsequently, it is essential to understand the attributes and mechanisms by which CSCs show their resistance to therapeutic agents. These aptitudes contribute to new bits of knowledge that give better therapeutic motivations to discover novel anticancer therapeutics. Accordingly, remedial procedures that emphasize focusing on CSCs and their microenvironmental niche are insufficient for conventional malignant growth treatments to eradicate the CSCs that, in any case, bring about therapy resistance. Mutual utilization of traditional therapies with CSC- specific agents may offer a promising technique for enduring cancer treatment as well as remedy.
Export Options
About this article
Cite this article as:
Ray Kumar Suman and Mukherjee Sukhes*, Cancer Stem Cells: Current Status and Therapeutic Implications in Cancer Therapy-A New Paradigm, Current Stem Cell Research & Therapy 2021; 16 (8) . https://dx.doi.org/10.2174/1574888X16666210203105800
DOI https://dx.doi.org/10.2174/1574888X16666210203105800 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry The Genetic Variants of IKZF1 Gene Linked with the Growing Risk of Childhood Acute Lymphoblastic Leukaemia
Current Molecular Medicine Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery In or Out Stemness: Comparing Growth Factor Signalling in Mouse Embryonic Stem Cells and Primordial Germ Cells
Current Stem Cell Research & Therapy Understanding Mesenchymal Cancer: The Liposarcoma-Associated t(12;16) (q13;;p11) Chromosomal Translocation as a Model
Current Genomics Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets The Role of Growth Factors in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity
Current Drug Safety Anti-Proliferative Effects of Novel Glyco-Lipid-Arsenicals (III) on MCF-7 Human Breast Cancer Cells
Medicinal Chemistry Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo
CNS & Neurological Disorders - Drug Targets Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry Steroidal Conjugates and Their Pharmacological Applications
Current Medicinal Chemistry CD45 Regulated Signaling Pathways
Current Topics in Medicinal Chemistry Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Pharmacological and Clinical Studies on Purine Nucleoside Analogs- New Anticancer Agents
Mini-Reviews in Medicinal Chemistry Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets The Shape of the Messenger: Using Protein Structure Information to Design Novel Cytokine-based Therapeutics
Current Pharmaceutical Design Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
Current Medicinal Chemistry Effective Downregulation of BCR-ABL Tumorigenicity by RNA Targeted CRISPR-<i>Cas13a</i>
Current Gene Therapy The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases - Part II
Current Medicinal Chemistry Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry